Halozyme Therapeutics (NASDAQ:HALO) Downgraded to Hold at StockNews.com

Halozyme Therapeutics (NASDAQ:HALOGet Rating) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

A number of other equities analysts also recently issued reports on HALO. Zacks Investment Research raised Halozyme Therapeutics from a “strong sell” rating to a “hold” rating and set a $37.00 price target for the company in a report on Monday, March 14th. Piper Sandler reduced their price objective on Halozyme Therapeutics from $43.00 to $42.00 in a research note on Wednesday, February 23rd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $47.83.

NASDAQ HALO opened at $41.74 on Tuesday. The company has a market cap of $5.75 billion, a P/E ratio of 15.18 and a beta of 1.32. The company has a debt-to-equity ratio of 4.00, a current ratio of 7.91 and a quick ratio of 7.45. The stock has a 50-day moving average of $37.28 and a two-hundred day moving average of $36.91. Halozyme Therapeutics has a 1-year low of $31.36 and a 1-year high of $51.57.

Halozyme Therapeutics (NASDAQ:HALOGet Rating) last announced its quarterly earnings data on Tuesday, February 22nd. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the Zacks’ consensus estimate of $0.35 by $0.04. Halozyme Therapeutics had a return on equity of 164.68% and a net margin of 90.84%. The business had revenue of $102.00 million during the quarter, compared to the consensus estimate of $97.10 million. On average, analysts anticipate that Halozyme Therapeutics will post 1.99 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the stock. Captrust Financial Advisors grew its holdings in Halozyme Therapeutics by 12.1% during the third quarter. Captrust Financial Advisors now owns 2,898 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 313 shares during the period. Mercer Global Advisors Inc. ADV boosted its stake in shares of Halozyme Therapeutics by 0.7% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 48,612 shares of the biopharmaceutical company’s stock valued at $1,955,000 after acquiring an additional 337 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Halozyme Therapeutics by 4.9% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 9,664 shares of the biopharmaceutical company’s stock valued at $393,000 after acquiring an additional 452 shares during the last quarter. Securian Asset Management Inc. boosted its stake in shares of Halozyme Therapeutics by 3.8% during the third quarter. Securian Asset Management Inc. now owns 12,764 shares of the biopharmaceutical company’s stock valued at $519,000 after acquiring an additional 464 shares during the last quarter. Finally, Fifth Third Bancorp boosted its stake in shares of Halozyme Therapeutics by 4.7% during the fourth quarter. Fifth Third Bancorp now owns 11,793 shares of the biopharmaceutical company’s stock valued at $474,000 after acquiring an additional 534 shares during the last quarter. 90.21% of the stock is currently owned by hedge funds and other institutional investors.

About Halozyme Therapeutics (Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Further Reading

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.